A cyclic undecamer peptide mimics a turn in folded alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Hoogerhout, Peter ^a   Kamphuis, Willem ^b   Brugghe, Humphrey F ^a   Sluijs, Jacqueline A ^b   Timmermans, Hans A M ^a   Westdijk, Janny ^a   Zomer, Gijsbert ^a   Boog, Claire J P ^a   Hol, Elly M ^b   van den Dobbelsteen, Germie P J M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN[1-42]; CYCLO[AMYLOID BETA PROTEIN[1-42] TYROSYLASPARAGINYLGLYCYLLYSINE] CONJUGATE; CYCLO[AMYLOID BETA PROTEIN[1-42] TYROSYLASPARAGINYLGLYCYLLYSINE] TETANUS TOXOID CONJUGATE; CYCLOPEPTIDE; OLIGOMER; TETANUS TOXOID; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; ANTIBODY; ANTIGEN;

ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOHISTOLOGY; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN AGGREGATION; AMINO ACID SEQUENCE; ANIMAL; BRAIN; CHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MOLECULAR GENETICS; PATHOLOGY; PROTEIN QUATERNARY STRUCTURE; PROTEIN SECONDARY STRUCTURE; WESTERN BLOTTING;

BOVINAE; MUS;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; ANTIGENS; BLOTTING, WESTERN; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES, CYCLIC; PLAQUE, AMYLOID; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY;

EID: 79955404847     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019110     Document Type: Article

References (43)

1. Blennow K, de Leon MJ, Zetterberg H, (2006) Alzheimer's disease. Lancet 368: 387-403.
2. Goedert M, Spillantini MG, (2006) A century of Alzheimer's disease 1. Science 314: 777-781.
3. Glabe CG, (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283: 29639-29643.
4. Haass C, Selkoe DJ, (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
5. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Muller R, et al. (2010) Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci 30: 10369-10379.
6. Klein WL, Stine WB Jr, Teplow DB, (2004) Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25: 569-580.
7. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, et al. (2007) Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 100: 23-35.
8. Walsh DM, Selkoe DJ, (2007) A beta oligomers- a decade of discovery. J Neurochem 101: 1172-1184.
9. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
10. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, et al. (2002) Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8: 1270-1275.
11. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562.
12. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, et al. (2008) Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 5: 194-196.
13. Brody DL, Holtzman DM, (2008) Active and passive immunotherapy for neurodegenerative disorders 2. Annu Rev Neurosci 31: 175-193.
14. Foster JK, Verdile G, Bates KA, Martins RN, (2009) Immunization in Alzheimer's disease: naive hope or realistic clinical potential? 1. Mol Psychiatry 14: 239-251.
15. Hawkes CA, McLaurin J, (2007) Immunotherapy as treatment for Alzheimer's disease. Expert Rev Neurother 7: 1535-1548.
16. Solomon B, (2008) Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease. Rejuvenation Res 11: 349-357.
17. Wisniewski T, (2009) AD vaccines: conclusions and future directions 3. CNS Neurol Disord Drug Targets 8: 160-166.
18. Woodhouse A, Dickson TC, Vickers JC, (2007) Vaccination strategies for Alzheimer's disease: A new hope? Drugs Aging 24: 107-119.
19. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, et al. (2003) Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15: 505-514.
20. Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, et al. (2006) Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine 24: 2275-2282.
21. Cao C, Lin X, Wahi MM, Jackson EA, Potter H Jr, (2008) Successful adjuvant-free vaccination of BALB/c mice with mutated amyloid beta peptides. BMC Neurosci 9: 25.
22. Lemere CA, (2009) Developing novel immunogens for a safe and effective Alzheimer's disease vaccine 2. Prog Brain Res 175: 83-93.
23. Lemere CA, Masliah E, (2010) Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6: 108-119.
24. Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, et al. (2009) Development of Affitope Vaccines for Alzheimer's Disease (AD)- From Concept to Clinical Testing 1. J Nutr Health Aging 13: 264-267.
25. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, et al. (2005) Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 58: 430-435.
26. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, et al. (2004) Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 165: 283-297.
27. Vasilevko V, Pop V, Kim HJ, Saing T, Glabe CC, et al. (2010) Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis 39: 301-310.
28. Olofsson A, Sauer-Eriksson AE, Ohman A, (2006) The solvent protection of alzheimer amyloid-beta-(1-42) fibrils as determined by solution NMR spectroscopy. J Biol Chem 281: 477-483.
29. Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, et al. (2009) Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 48: 1870-1877.
30. Oomen CJ, Hoogerhout P, Bonvin AM, Kuipers B, Brugghe H, et al. (2003) Immunogenicity of peptide-vaccine candidates predicted by molecular dynamics simulations. J Mol Biol 328: 1083-1089.
31. Oomen CJ, Hoogerhout P, Kuipers B, Vidarsson G, van AL, et al. (2005) Crystal structure of an Anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design. J Mol Biol 351: 1070-1080.
32. Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ, (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 278: 11612-11622.
33. Brugghe HF, Timmermans HA, Van Unen LM, Ten Hove GJ, Van de Werken G, et al. (1994) Simultaneous multiple synthesis and selective conjugation of cyclized peptides derived from a surface loop of a meningococcal class 1 outer membrane protein. Int J Pept Protein Res 43: 166-172.
34. Drijfhout JW, Hoogerhout P, (2000) Methods of preparing peptide-carrier conjugates. In: Chan WC, White PD, editors. Fmoc Solid Phase Peptide Synthesis: A Practical Approach: Oxford University Press pp. 229-241.
35. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial 1. Lancet 372: 216-223.
36. Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ, (2006) Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res 9: 77-84.
37. Perrin RJ, Fagan AM, Holtzman DM, (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461: 916-922.
38. Huitinga I, Rademaker M, Klioueva N, (2008) The art of brain banking in Europe: ethical, legal and practical guidelines for donor recruitment, tissue handling and tissue distribution. J Neural Transm 115: 1715.
39. Zeng H, Zhang Y, Peng L, Shao H, Menon NK, et al. (2001) Nicotine and amyloid formation. Biol Psychiatry 49: 248-257.
40. Sarria AJ, Lieber JG, Nordeen SK, Evans RM, (1994) The presence or absence of a vimentin-type intermediate filament network affects the shape of the nucleus in human SW-13 cells. J Cell Sci 107 (Pt 6): 1593-1607.
41. Zomer G, Hamzink M, de Haan A, Kersten G, Reubsaet K, (2009) Development and optimization of a quantitative Western blot and dot blot procedure for the determination of residual host cell proteins present in inactivated polio vaccine using GZ11 based signal reagent. In: Shen X, Yang XL, Zhang XR, Cui ZJ, Kricka LJ, editors. Bioluminescence and Chemiluminescence Light Emission: Biology and Scientific Applications: World Scientific pp. 287-290.
42. Westdijk J, van den IJssel J, Thalen M, Beuvery C, Jiskoot W, (1997) Quantification of cell-associated and free antigens in Bordetella pertussis suspensions by antigen binding ELISA. J Immunoassay 18: 267-284.
43. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.